6-Spirocycloalkylamino 5-nitropyrimidines

ABSTRACT

Novel pteridines of formula (I), ##SPC1## 
     wherein R is a lower alkyl group, optionally substituted with a hydroxy group and R 1  and R 2  are the same or different and each is a lower alkyl group having together at least 3 carbon atoms or R 1  and R 2 , together with the carbon atom in the pteridine ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure, and their method of preparation. 
     The above compounds have bacteriostatic activity.

The present invention relates to derivatives of pteridine, theirchemical synthesis and pharmaceutical formulations containing them. Thespecification also describes compositions and pharmaceuticalformulations comprising these pteridines in combinations which areuseful in the treatment of microbial infections.

It is already established that the compounds2-amino-4-hydroxy-6-hydroxymethyl-7,7-dimethyl-7,8-dihydropteridine and2-amino-4-hydroxy-6-methyl-7,7-dimethyl-7,8-dihydropteridine or theirtautomers or pharmaceutically acceptable saltss thereof, havebacteriostatic activity, being particularly effective against Cl.perfringens and Derm. dermatonomous, as disclosed in the specificationsof British Patent No. 1303171 and Application No. 36289/70 (BelgianPatent No. 770,577).

It has now been found that the novel pteridines represented by thefollowing formula (I) or their tautomers or pharmaceutically acceptablesalts thereof, ##SPC2##

Wherein R is a lower alkyl group, optionally substituted with a hydroxygroup, and R¹ and R² are the same or different and each is a lower alkylgroup having together at least 3 carbon atoms or R¹ and R², togetherwith the carbon atom in the pteridine ring structure, form aspirocycloalkyl ring system having 4 to 6 carbon atoms outside thepteridine ring structure, are also useful as antagonists of microbialmetabolism.

As used herein and throughout the specification, the term "lower alkylgroup" refers to a straight or branched chain alkyl group which, unlessotherwise specified, has 1 to 4 carbon atoms.

In the above formula, preferred compounds are those wherein R is ahydroxyalkyl group, in particular a hydroxymethyl group. Moreover thosecompounds wherein R¹ and R², together with the carbon atom in thepteridine ring structure, form a spirocyclohexyl group, or especiallythose wherein R¹ and R² are both alkyl groups, in particular ethylgroups, are further preferred. Thus the compounds2-amino-4-hydroxy-6-hydroxymethyl-7,7-diethyl-7,8-dihydropteridine andless preferably2-amino-4-hydroxy-6-hydroxymethyl-7-spirocyclohexyl-7,8-dihydropteridinehave been found to be particularly useful in the treatment of microbialinfections.

According to the present invention, therefore, there are provided in oneaspect the novel compounds of formula (I).

The above compounds and their salts inhibit one of the enzymes involvedin the biosynthesis of dihydrofolic acid, namelyhydroxymethyldihydropteridine pyrophosphokinase, which is essential tothe growth of microorganisms, for instance bacteria. They can thus beused in in vitro pharmacological investigations in clinical anddiagnostic tests establishing, for instance, the properties of bacteria.When used as bacteriostats they may be present in a concentration of 50to 500, in particular 110 to 180 mg of base/ml of the solution in whichthe organism grows in the absence of a compound. A further use of thecompounds, when in solution, is in the treatment of wounds, for exampleafter surgery, to prevent the growth of bacteria. Moreover the compoundsof formula (I) and their salts manifest unexpectedly low toxicity inmammals or birds e.g. poultry, which makes them particularly suitablefor application against microbial infections in such hosts undercircumstances hereinbelow described.

Tetrahydrofolate co-factors are essential metabolites in all cells forthe biosynthesis of purines, thymidylic acid, serine and several otherbiologically important compounds. Most of these co-factors are onecarbonadducts of tetrahydrofolic acid. The ultimate source of these for higheranimals and man is food, containing preformed folates usually in theform of vitamins.

In microorganisms, the co-factors are synthesised from simplerchemicals. Generally the bio-synthetic process first provides`dihydropteridine` (Pt), i.e. 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine (HMPt) pyrophosphate ester, from its immediateprecursor HMPt in the presence of the enzymehydroxymethyldihydropteridine pyrophosphokinase (HMPPS). Pt thencondenses with p-aminobenzoic acid (pAB) in the presence of the enzymedihydropteroate synthetase to form dihydropteroic acid (DPtA). Thisintermediate further condenses with a glutamate to form dihydrofolicacid (DFA or `folate`) which is then enzymatically reduced to providethe essential tetrahydrofolate in, for instance, bacteria and othermicro-organisms.

The provision of the `folate` from the basic building blocks, i.e.pteridine, pAB, and glutamate, and the further conversion of this intothe tetrahydrofolate is known to be inhibited in two different ways. Forinstance sulphonamides displace pAB in the above reaction scheme.Because of their close structural resemblance to pAB, sulphonamides orsimilar other `competitors` enter the biosynthesis and prevent theformation of DPtA, and of DFA, and are therefore antimetabolites for themetabolite pAB. It is also known that compounds which are `inhibitors`of the enzyme dihydrofolic acid reductase block the synthetic stepleading to tetrahydrofolate. A considerable number of pyrimidinederivatives show substantial anti-microbial properties on the basis ofsuch blockage.

It was established later that such inhibitors may act synergisticallywith sulphonamides, i.e. there can be a sequential double blockade and astrong mutual potentiation of the anti-bacterial effects of the twomaterials. The range of anti-microbial action exerted by suchcombinations is considerably wider than that expected from the activityof either drug, and organisms which are only marginally sensitive to theindividual agents become very sensitive to the combinations.

It was also suggested hypothetically that antimetabolites to Pt couldinhibit the biosynthesis of DPtA (and DFA) (cf. Hitchings and BurchallAdvances in Enzymology, 27, 417-468 (1965)) but compounds so far testedfor the purpose have been disappointing, being either inactive or tootoxic or sometimes both (cf. the compounds described in British PatentNos. 981,506 and 987,916).

It has been established that, for antimicrobial purposes, it is aprerequisite for the effective antagonism of Pt that the compound shouldbe an inhibitor of HMPPS without also acting as an antimetabolite to thedihydropteridine that serves as a cofactor for the hydroxylation ofphenylalanine and tyrosine, precursors of the catecholamines, such asnorepinephrine, that have important actions as regulators ofcardiovascular systems. Such an antimetabolic effect could lead toprohibitive toxicity to avian or mammalian species, which are normallythe hosts infected with the microbes.

It has now been found that the compounds of formula (I) and their saltsfulfil the above requirements i.e. inhibition of HMPPS combined with lowtoxicity to host species, as demonstrated for instance in chicks andrats. These compounds not only inhibit the growth of microorganisms ontheir own, albeit to a limited extent with certain bacteria, such asStaphylococcus aureus, Streptococcus pyogenes, Streptococcus faecalis,Escherichia coli, Salmonella typhi, Proteus vulgaris, Pseudomonasaerugenosa, Pasteurella multocida among others, but have been found toact with a most remarkable synergistic effect when combined with acompetitor of p-aminobenzoic acid, i.e. sulphonamides and similarcompounds, or with selective inhibitors of dihydrofolic reductase, i.e.pyrimidines and related compounds, or with a combination of both ofthese types of anti-microbial agents. This potentiating effect of thecompounds of formula (I) is the subject of co-pending cognate BritishPatent Application No. 36774/71.

In that application there is described and claimed a composition fortesting or treating microbial systems or infections, comprising aneffective potentiating amount of a compound of formula (I) incombination with an effective amount of a competitor or inhibitor, orboth, as herein defined.

The microbial infections against which these combinations are effectiveare protozoal or bacteria infections caused by those microorganismswhich synthesise at least a substantial part of their tetrahydrofolatecofactor requirements. More specifically these infecting microorganismsare those which adequately absorb the pharmaceutical combinationsdisclosed herein and further are those in which these combinations havea synergistic effect in interfering with the de novo synthesis of therequired tetrahydrofolate co-factors. For example, the compositionsdescribed have been found to be useful in the treatment of infectionscaused by Staphylococcus aureus, Pseudomonas aerugenosa and Pasteurellamultocida.

It has been found specifically that, when compounds of formula (I) arecombined with an amount of the competitor and/or the inhibitor which isnot ordinarily sufficient to be effective as an antimicrobial agent inits own right, the combination of a compound of formula (I) with thisnormally ineffective amount of the competitor and/or the inhibitorprovides a composition which in totality acts as an effectiveantimicrobial agent. This is especially notable when the amount of thecompound of formula (I) is so low that it has substantially no microbialeffect at the particular level, yet in the combination the potentiationis marked, in some instances very marked. Thus by using an effectivepotentiating amount of a compound of formula (I) together with thecompetitor and/or the inhibitor, it is now possible to reducesignificantly the amount of the competitor and/or the inhibitor requiredto inhibit the growth of these bacteria.

In accordance with the above therefore, the term "an effective amount"used in conjunction with the terms a dihydrofolic reductase `inhibitor`and a para-aminobenzoic acid `competitor` means either (a) an amount ofthe `inhibitor` or `competitor` which is effective to a degree as anantimicrobial agent in its own right but which is potentiated by the useof a compound of formula (I) or (b) an amount of the `inhibitor` or`competitor` which is ineffective as an antimicrobial agent by whichwhen combined with a compound of formula (I) provides a compositionwhich is an effective antimicrobial agent. An "effective potentiatingamount" means an amount of the compound of formula (I) which increasesthe activity of an inhibitor and/or a competitor so as to provide animproved or adequate effectiveness for the whole combination.

It should be emphasised that the inhibition of the biosyntheticprocesses by such means could be termed as competitive antagonism in allthree instances, and there might be potentiation between all three typesof agents. The terms `inhibitor`, `competitor`, and `potentiation` by acompound of formula (I) are arbitrary and should only serve asconvenient names for the appropriate type of components in combinationproducts described and claimed in the specification of theafore-mentioned cognate application.

The inhibiting activity against HMPPS of a selected compound of formula(I) can, for instance, be tested by monitoring the transfer of theterminal phosphate of adenosine triphosphate ATP-γ-P³² to`dihydropteridine`. It was found that the concentrations required for50% inhibition of the formation of Pt (IC₅₀) in such tests are wellcorrelated and within the margin of error obtained by other relevanttests in this respect, which measure the inhibition of either of the twoenzymes involved in the formation of HMPt and DPtA. Such inhibition may,for instance, be easily and simply carried out by incubating an extractof E. coli with pAB-7-C¹⁴, ATP, Mg and `dihydropteridine`. The formationof the dihydropteroate-C¹⁴ can be quantitatively assayed afterseparating the unreacted pAB substrate, for instance by chromatography.It has been found that compounds possessing in such tests an IC₅₀ valueof about 100μM, or less, usually below 50μM represent compounds exertinga useful potentiating effect, provided their toxicity in the appropriatevertebrates is acceptable. Preferably the value is 25μM or less, such asin the range between 2 to 12μM. Generally a value below 7μM isdesirable.

As explained above, for the purpose disclosed it is essential that thecompound of formula (I) should not have a prohibitive toxicity to themammalian or avian hosts' cardiovascular systems. While low toxicity istherefore an essential requirement, a therapeutic index incorporatesboth the activity and toxicity values pertinent to the presentdisclosure and could be used with advantage for the selection ofpotentiating compounds of formula (I).

The therapeutic index is defined as the ratio of the maximum tolerateddose to the minimum effective dose and in most cases is preferablygreater than 10, suitably at least 5 and in exceptional circumstances atleast about 3 for humans, but possibly as low as 2 for animals.

Although the art is aware of many compounds which are known competitorsof para-aminobenzoic acid and are antimicrobials, the sulphur compoundswhich are disclosed as antimicrobial agents from the top of page 994 topage 1007 of the Merck Index, 8th Edition, 1968 are presented by way ofexample only.

Of the known compounds which are competitors, the following sulphonamidecompounds (or pharmaceutically acceptable salts thereof) are preferredfor the purpose described.

Sulphanilamide, sulphadiazine, sulphamethisazole, sulphamethizole,sulphapyridine, sulphathiazole, sulphamerazine, sulphamethazine,sulphisoxazole, sulphadoxine, sulphasomidine, sulphachlorpyridazine,2-(p-aminobenzene)-sulphonamido-3-methoxypyrazine(Kelfizina),α-amino-p-toluenesulphonamide, 5-sulphanilamido-2,4-dimethyl pyrimidine,4-(N'-acetyl sulphanilamido) -5,6-dimethoxy pyrimidine,3-sulphanilamido-4,5-dimethyl isoxazole,4-sulphanilamido-5-methoxy-6-decyloxy pyrimidine, sulphamonomethoxine,4-p-(8-hydroxy-quinilinyl-4-azo)-phenyl sulphanilamido-5, 6-dimethoxypyrimidine, sulphadimethoxine, sulphamethoxazole, sulphaquinoxaline, andp-(2 methyl-8-hydroxy-quinolinyl-(5)-azo)phenylsulphanilamido-5,6-dimethoxy pyrimidine. Examples of a non-sulphonamidetype of competitor are p-amino salicylic acid (PAS) andp,p'-diaminodiphenylsulphone.

Similarly, although many compounds are known which inhibit dihydrofolicreductase and act as antimicrobial agents, the compounds disclosed inthe following patents are presented by way of example of compoundssuitable for use for the purpose disclosed.

U.S. Pat. Nos. 2,658,897; 2,767,183; 3,021,332; 2,937,284; 3,322,765;2,909,522: 2,624,732; 2,579,259; 2,945,859; 2,576,939; 2,926,166;2,697,710; 2,749,345; and 2,749,344.

The following inhibitors (or pharmaceutically acceptable salts thereof)are preferred for the combinations described, however:

2,4-diamino-6-ethyl-5-p-chlorophenylpyrimidine (pyrimethamine),2,4-diamino-5-(3'4',5'-trimethoxybenzyl)-pyrimidine (trimethoprim),2,4-diamino-5-(3'4'-dimethoxybenzyl) pyrimidine (diaveridine),2,4-diamino-5-(2'-isopropyl-4'-chlorophenoxy) pyrimidine,2,4-diamino-5-methyl-6-sec-butylpyrido (2,3-d) pyrimidine,2,4-diamino-5-methyl-6-benzylpyrido(2,3-d) pyrimidine,2,4-diamino-6-benzylpyrido(2,3-d) pyrimidine,2,4-diamino-5-6-trimethylenequinazoline,2,4-diamino-5,6-tetramethylenequinazoline,2,4-diamino-5-(2',4'5'-trimethoxybenzyl) pyrimidine,2,4-diamino-5-(2'-ethyl-4',5-dimethoxybenzyl) pyrimidine,2,4-diamino-5-(2'-methyl-4',5'-dimethoxybenzyl) pyrimidine.

However, the most preferred combinations include those combining acompound of formula (I), especially that wherein R is a hydroxymethylgroup and R¹ and R² are both ethyl groups, with sulphadiazine,sulphamethoxazole, sulphadoxine or sulphaquinoxaline as competitors, orwith trimethoprim, diaveridine or pyrimethamine as inhibitors. In viewof possible synergistic advantages of using certain competitors andinhibitors in combination against particular diseases, and thepotentiating effect of compounds of formula (I) on both of these typesof antibacterial compounds, it has been preferred to formulate triplecombinations, comprising a compound of formula (I) with one of theabove-mentioned preferred competitors, and one of such inhibitors. Forexample, combinations of sulphadiazine/trimethoprim,sulphamethoxazole/trimethoprim, sulphadoxine/trimethoprim orsulphaquinoxaline/diaveridine, each together with a compound of formula(I), give improved effectiveness when compared with the components aloneor with pairs of them.

The compounds of formula (I) either alone or together with thecompetitor and/or the inhibitor, may be presented in association with acarrier in pharmaceutical formulations suitable for parenteral, topical,rectal or oral administration. The formulations for oral or rectaladministration are advantageously presented in discrete units, such astablets, capsules, cachets, ampoules or suppositories, each containing apredetermined amount of each compound, but may also be presented as apowder, as granules, as a solution or suspension in an aqueous ornon-aqueous liquid, or as an ointment or paste for topicaladministration. For parenteral use, the formulations incorporating anaqueous or non-aqueous liquid carrier must be sterile and be presentedin sealed containers. The formulations may be made by any of the knownmethods and may include one or more of the following accessoryingredients:

diluents, solutes to render the solution isotonic with the blood,buffers, flavouring, binding, dispersing, surface-active, thickening,lubricating and coating materials, preservatives, bacteriostats,antioxidants, suppository and ointment bases, and any other acceptableexcipients.

In another aspect of the present invention, therefore, there is provideda pharmaceutical formulation comprising a compound of formula (I) incombination with a pharmaceutically acceptable carrier. In yet anotheraspect the present invention provides a method of making apharmaceutical formulation by admixing the compound of formula (I) witha carrier by known techniques. The specification of the afore-mentionedcognate application further discloses and claims a pharmaceuticalformulation comprising a composition, as hereinbefore defined, togetherwith a carrier, and its method of preparation, by admixing thecomposition with the carrier by known, techniques.

Formulations containing the compound of formula (I) in association witha competitor or an inhibitor may also be presented in the form of a kit,which comprises separately packaged units or dosages of these componentswith instructions for use in a combined form. The instructions may alsospecify the manner of administration and indications for which theformula is suitable.

The compounds of formula (I), either for use alone or in associationwith a competitor and/or inhibitor, and also the competitors andinhibitors, may be presented in the form of their pharmaceuticallyacceptable salts of a mineral or organic acid, for example hydrochloricacid, hydrobromic acid, sulphuric acid, acetic acid, citric acid,tartaric acid, lactic acid, maleic acid or salicylic acid, or,especially for the sulphonamide competitor, of a base, such as sodiumhydroxide, potassium hydroxide, tetramethyl ammonium hydroxide orammonia.

The ratios in which the therapeutically active compounds of formula (I)are utilized in the compositions described in this specification can bevaried between wide limits. Depending on the nature and circumstance ofuse, the compositions may contain the compound of formula (I) with thecompetitor and/or the inhibitor in appropriate proportions and dosages.For instance, in cases of uses in vivo it is often desirable to maintaina certain proportion of components in the blood serum or tissue fluids,preferably for a prolonged period. Depending on the various absorption,discharge or decomposition rates of the components, the initialquantities and proportions of the ingredients of the formulation can bedifferent from that aimed at in the tissues in vivo. The formulationsand dosages recommended for the general treatment of a particular humanor animal disease must be adjusted according to the particularrequirements of the recipients of the disease, the known activities ofthe competitor or inhibitor component against the causative organism,the half life and the toxicity of the components in vivo, and otherpractical requirements.

For example the composition or pharmaceutical formulation may containfrom about 1 to 30 parts by weight, preferably 5 to 15 parts, of thecompound of formula (I), or an equivalent amount of a salt thereof, and1 to 30 parts, preferably 5 to 15 parts, of a competitor, or anequivalent amount of a salt thereof, and/or one part of an inhibitor, oran equivalent amount of a salt thereof.

Dosage will vary depending upon the infecting organism but underordinary circumstances up to about 60 mg/kg each of a compound offormula (I) and competitor, and up to about 7.5 mg/kg of inhibitor, incombination, can be administered daily in several doses. The compositionor pharmaceutical formulation can be administered to human patients inunit dosage forms which contain up to 750 mg of the compound of formula(I), and up to 750 mg of the competitor and/or up to 25 mg of theinhibitor. Preferably for adult dosages the amount of the compound offormula (I) would be about 200 mg, that of the competitor about 200 mgand/or that of the inhibitor about 25 mg.

The pharmaceutical formulation comprising the compound of formula (I) incombination with the competitor and/or the inhibitor is also usable insolution for irrigating wounds, for example after surgery, so as toprevent the growth of bacteria. For example, an antibacterial solutionhaving the following preferred concentration of components may be used:

1-30 mg/ml of the compound of formula (I), 1-30 mg/ml of the competitorand/or 0.03-1 mg/ml of the inhibitor, in a pharmaceutically acceptablesolvent, suitable for external use.

The potentiating effect of compounds of formula (I) can be demonstratedand utilized in vitro relatively easily for research and practicalpurposes. Such possibilities include diagnosis and the identification ofthe bacterial flora of individuals and the consequential selection ofclinical treatment schedules.

The various combinations can be incorporated in porous discs (such asfilter paper discs) or in Agar Nutrient or other media for bacterialgrowth for determining susceptibility. Those articles incorporating thecompound of formula (I) with a competitor and/or an inhibitor compoundmay be distributed or sold to doctors, hospitals and clinics for theabove purposes. A typical testing disc may be impregnated with asolution containing 5 to 50 μg/ml of a para-aminobenzoic acidcompetitor, 0.5 to 5 μg/ml of a dihydrofolic reductase inhibitor, andabout 10 to 100 μg/ml of a compound of formula (I) in a mediumcomprising a mixture of an aqueous infusion and papain digest of horsemuscle.

Furthermore, such pharmacological tests involving potentiatedcompetitors or inhibitors may also be useful for the characterisation ofbacteria according to their sensitivity and to their particularresistance for instance to a competitor when used alone, and suchinvestigations involving a variety of formulations as described hereinalso form the basis of determining the compositions of selectedformulations for general treatment purposes. The toxicity of compoundsof formula (I) is generally considerably lower than that of thecompetitors or inhibitors commonly used, which may enable the clinicianto maintain or increase the effectiveness of the antibacterial activityof the formulation with a concurrent increase of the therapeutic ratioor decrease in the toxic or side-effects of the medicament.

In addition to the above, compounds of formula (I) have been found topotentiate the activity of the aforementioned competitors and/orinhibitors against infections with microorganisms in domestic animals,including poultry, for example against Pasteurella multocida butespecially against the protozoal disease coccidiosis. Such tripleformulations comprising a compound of formula (I) together with acompound such as sulphaquinoxaline and an inhibitor such as diaveridineare effective in lower concentrations than the competitor or inhibitorcomponents alone and possess an enhanced activity, being effectiveagainst all relevant Eimeria species causing this disease in poultry.

The compounds of formula (I) may be prepared by the reductivecyclisation of a compound of formula (II), ##SPC3##

wherein R, R¹ and R² are as defined above and Z is a ketonic oxygen atomor a protecting group therefor, such as a semicarbazone group or anoxime group, prepared according to the procedures diclosed by Pfleidererand Zondler (Chem. Ber. 99, 3008 (1966)) and the specifications ofBritish Patent No. 1303171 and of co-pending Bristish Patent ApplicationNo. 36289/70 (Belgian Patent No. 770,577) respectively.

The method described in British Patent Application No. 36289/70,however, is particularly preferred.

In this method, a compound R¹ R² C = CHR (VI), wherein R, R¹ and R² areas defined above, undergoes an addition reaction with a nitrosyl halide,prepared in situ, and the resulting nitrosohalide (V) is converted tothe oxime (IV) by reaction with ammonia solution. Reacting the oxime(IV) with a 2-amino-4-halogeno-6-hydroxy-5-nitropyrimidine (III)provides the pyrimidine ketoxime (II) which is then reductively cyclisedto give the pteridine (I), as shown in the following sequence: ##SPC4##

The compound of formula (VI) wherein R is a hydroxyalkyl group may inturn be prepared from the ketone R¹ R² C=O (IX) by reacting this with atrialkylphosphonoester (VIII) and reducing the ester (VII) so formed togive the alcohol (VI). ##EQU1##

If a pteridine having R¹ and R² as different substituents is required,then a racemic mixture of two stereoisomers of the nitrosohalide (V)will be obtained in view of the asymmetric carbon atom present.Separation of the two isomers by conventional techniques known in theart at this stage may be advantageous.

According to the present invention in further aspects there are alsoprovided:

1. The methods described herein for preparing any of the compounds offormula (I), comprising effecting reductive cyclisation of the compoundsof formula (II).

2. The methods described herein for preparing any of the compounds (II),wherein Z is an oxime group, from (IV), (IV) from (V) or (VI) and (VI)from (IX).

3. Compounds of formula (I), (II), wherein Z is an oxime group, (IV) and(V), whenever prepared by a method as defined under (1) or (2).

4. As novel compounds of value as chemical intermediates: compounds offormula (II), (IV) and (V).

5. A pharmaceutical formulation comprising a compound of formula (I) ora salt thereof in combination with a pharmaceutically acceptablecarrier, whenever prepared by the method herein described.

The following Examples illustrated the invention but are in no wayintended to limit the scope of the invention.

Temperature are in degrees Celsius.

EXAMPLE A Preparation of2-amino-4-hydroxy-6-hydroxymethyl-7,7-diethyl-7,8-dihydropteridine.(I,R=CH₂ OH; R¹ =R² =Et) EXAMPLE 1 Ethyl 3-ethylpent-2-enoate (VII) (R¹=R² =Et)

Sodium hydride (6 g) was placed in a flask with sodium dried benzene(100 ml) and the flask was flushed with oxygen-free dry nitrogen. Tothis solution was added a slight excess of triethylphosphonoacetate(VIII) (Alk=Et) (61.7 g) over a period of 1.5 h and the temperature wasmaintained <15° during the addition. The mixture was stirred at thistemperature for an additional 1 h and then treated dropwise withpentan-3-one (IX), (R¹ =R² =Et) (21.5 g). After addition of the ketonewas complete the reaction mixture was stirred at room temperature untilthe solid sodium diethyl phosphate had precipitated (approx. 10 h). Themother liquor was decanted from the solid, which was washed with benzene(4 × 25 ml). The benzene extracts were combined and evaporated in vacuoto give a pale yellow oil (29 g) which was distilled in vacuo to giveethyl 3-ethylpent-2-enoate (VII) (21.8 g, yield 56%) as a colourlessoil, b.p. 52°-54°/4 mm. Hg.

EXAMPLE 2(a) 3-Ethylpent-2-en-1-ol.(VI) (R¹ =R² =Et)

Ethyl 3-ethylpent-2-enoate (VII) (42.3 g) in dry ether (400 ml) wastreated dropwise with a 70% solution (in benzene) of a slight excess ofsodium dihydro bis ethoxymethoxy aluminate (S.D.A.) (86.1 g), thetemperature being maintained at 0° until the addition of the reducingagent was complete. The reaction mixture was then stirred at roomtemperature for 6 h and the excess S.D.A. was destroyed by the carefuladdition of water. The solid sodium aluminate which precipitated wasfiltered off and the filtrate extracted with ethyl acetate (4×50 ml).The combined extracts were washed with brine, dried over sodium sulphateand the solvent removed. The resulting pale yellow oil (23 g) wasdistilled to give 3-ethylpent-2-en-1-ol (VI) (18.5 g, yield 60%) as acolourless viscous oil b.p. 60°/4 mm. Hg.

EXAMPLES 2(b) 3-Ethylpent-2-en-1-ol (VI) (R¹ =R² =Et)

A slurry of lithium aluminium hydride (L.A.H.) (8.2 g) in dry ether wasadded dropwise to a solution of ethyl 3-ethylpent-2-enoate (VII) (33.7g) in dry ether (100 ml) at 0°. After the addition of the L.A.H. wascomplete the mixture was stirred at room temperature for 2 h. The excessL.A.H. was destroyed at 0° by adding a saturated solution of sodiumsulphate. The solution was filtered and the filtrate extracted withethyl acetate and worked up as described in Example 2(a) to give thealcohol (VI) (19 g, yield 77%).

EXAMPLE 3 3chloro-3-ethyl-2-nitroso-pentan-1-ol. (V) (R=CH₂ OH; R¹ =R²=Et)

Concentrated hydrochloric acid (23 ml) was added dropwise over 1.5 h toa mixture of 3-ethylpent-3-en-1-ol (VI) (23 g) and amyl nitrite (22.4 g)in glacial acetic acid (46 ml) at 0° (ice-salt bath). After the additionof the acid was complete the mixture was stirred at this temperature for30 min, then cooled in an acetone-carbon dioxide bath for 15 min when awhite paste formed. The solid was filtered off, washed with water andcold methanol and recrystallised from benzene to give the nitroschloride(V) (13 g, yield 36%) as colourless crystals, m.p. 110°.

EXAMPLE 4 3-Amino-3-ethyl-1-hydroxy-pentan-2-one oxime hydrochloride(VI) (R=CH₂ OH; R¹ =R² =Et)

3-Chloro-3-ethyl-2-nitroso-pentan-1-ol (V) (10 g) was placed in athree-necked round-bottomed flask and treated with a saturated solutionof ammonia in methanol. The flask was stoppered, each stopper beingsecured with copper wire, and the mixture was stirred at roomtemperature for 2days. A clear yellow solution was obtained. The solventwas removed in vacuo at room temperature and the yellow oil obtained wastriturated with hot benzene and the benzene decanted. The residue wasdissolved in ethanol and the insoluble ammonium chloride present wasfiltered off. The ethanol was removed in vacuo at room temperature andthe residual yellow oil was treated with hot acetone to give a whitesolid which was filtered off, washed with acetone and recrystallisedfrom butan-2-ol to give the ketoxime hydrochloride (VI) (5 g; yield 46%)as colourless needles, M.Pt. 182°-184°.

EXAMPLE 52-Amino-4-hydroxy-6(1,1-diethyl-3-hydroxy-2-hydroxyiminopropylamino)-5-nitropyrimidine(II) (R=CH₂ OH; R¹ =R² =Et) 1=R² =Et)

A suspension of 2-amino-4-chloro-6-hydroxy-5-nitropyrimidine (III)(Hal=Cl) (2.6 g) in dry ethanol (50 ml) was treated with3-amino-3-ethyl-1-hydroxy-pentan-2-one oxime hydrochloride (VI) (2.66 g)and dry triethylamine (2.89 g) and the mixture was refluxed for 8 h. Thesolution was filtered and the filtrate evaporated to dryness in vacuo atroom temperature. The yellow oil obtained was treated with cold waterand the yellow solid which precipitated was filtered off and washed withwater. Recrystallisation from water in the presence of charcoal gave thenitropyrimidine oxime (II) (1.3 g; yield 30%) as a fine white solid m.p.<250° (decomp.).

EXAMPLE 62-Amino-4-hydroxy-6-hydroxymethyl-7,7-diethyl-7,8-dihydropteridine (I)(R=CH₂ OH; R¹ =R² =Et)

Sodium dithionite was added portionwise to a warm solution of2-amino-4-hydroxy-6-(1,1-diethyl-3-hydroxy-2-hydroxyiminopropylamino)-5-nitropyrimidine(II) (450 mg) in 0.1M sodium hydroxide until the colour changed from redto very pale yellow. A solid product was not obtained either on coolingor on adjusting the pH. In order to separate the product from inorganicmaterial the solution was evaporated and the product extracted withethanol and the inorganic material was filtered off. This extraction wasrepeated and the combined extracts were evaporated to dryness in vacuo.The residue was dissolved in the minimum quantity of water and placed ona column of Amberlite (C.G.50) ion exchange resin (2.5 × 28 cm). Elutionwith water gave two main fluorescent bands. Evaporation of the solutioncontaining the first band gave the 6-carboxaldehyde derivative of thetitle compound (10 mg, yield 3%) as a bright orange powder, whilst thesecond band gave the 7,8-dihydropteridine (I) (160 mg, yield 44.5%) as abright yellow powder, m.p. <300° decomp.

EXAMPLE B Preparation of2-Amino-4-hydroxy-6-hydroxymethyl-7-spirocyclohexyl-7,8-dihydropteridine(I) (R=CH₂ OH; R¹ R² =spirocylohexyl). EXAMPLE 1 Ethyl cyclohexylideneacetate (VII) (R¹ R² =spirocyclohexyl).

Sodium dried benzene (200 ml) was added to a flask containing sodiumhydride (16 g) and the flask was flushed with oxygen-free dry nitrogen.To this mixture was added, over 1 h, a slight excess oftriethylphosphonoacetate (VIII) (Alk=Et) (164.3 g) keeping thetemperature at 0°. The reaction mixture was stirred for an additionalhour at 0° and then treated with cyclohexanone (IX) (R¹ R²=spirocyclohexyl) (65.4 g) at the same temperature.

After the addition of the cyclohexanone was complete (≈40 min) themixture was stirred at room temperature for 3 h; stirring becamedifficult after this time due to a gummy precipitate of sodium diethylphosphate.

The mixture was then heated at 60°-65° for 15 min during which time itwas stirred without difficulty. The mixture was cooled to 15° and thebenzene solution was decanted and the solid washed with benzene. THecombined mother liquor and washings were evaporated to give a paleyellow oil which on distillation gave ethyl cyclohexylidene acetate(VII) (62 g; yield 55.4%) as a colourless oil, b.p. 86°-88°/2 mm. Hg

EXAMPLE 2(a) 2-Cyclohexylidene ethanol (VI) (R¹ R² =spirocyclohexyl)

A 70% solution (in benzene) of sodium dihydrobisethoxymethoxy aluminate(100g) was added portionwise to ethyl cyclohexylidene acetate (VII)(58.8 g) in dry ether (300 ml) at 0°. The reaction mixture was stirredfor 6h at room temperature and the excess reducing agent was destroyedby the addition of water. The solid sodium aluminate was filtered offand the filtrate extracted with ethyl acetate (4 × 50 ml). The combinedextracts were washed with brine, dried over sodium sulphate and thesolvent evaporated in vacuo. A pale yellow oil was obtained which ondistillation gave 2-cyclohexylidene ethanol (VI) (31 g; yield 70%) as acolourless oil, b.p. 80°/2mm Hg.

Example 2(b) 2-Cyclohexylidene ethanol (VI) (R¹ R² =spirocyclohexyl)

A solution of ethyl cyclohexylidene acetate (VII) (60 g) in dry ether(300ml) was cooled to 0° and treated portionwise with a slurry oflithium aluminium hydride (15 g) in dry ether (150 ml), the temperaturebeing kept below 5° during the addition. The reaction mixture wasstirred for 15 min at this temperature and for an additional 20 min atroom temperature. The excess hydride was destroyed with saturated sodiumsulphate and the ethereal solution worked up as above to give thealcohol (VI) (23 g; yield 51%) as a colourless oil.

EXAMPLE 3 3-Chloro-2-nitroso-3-spirocyclohexylpropan-1-ol (V) (R=CH₂ OH;R¹ R² =spirocyclohexyl).

2-Cyclohexylidene ethanol (VI) (23 g) was dissolved in glacial aceticacid (76 ml). Amyl nitrite (21.5 g) was added and the mixture was cooledin an ice-salt bath. The cooled solution was treated dropwise with coldconcentrated hydrochloric acid (23 ml) with stirring. After the additionof the acid was complete the reaction mixture was stirred at the sametemperature for 30 min, followed by cooling in an acetone-carbon dioxidebath for 10 min. The buff-coloured solid was filtered off, washed withcold methanol and recrystallised from acetone to give thenitrosochloride (V) (15 g; yield 43%) as colourless needles, m.p. 130°.

EXAMPLE 4 3-Amino-1-hydroxy-3-spirocyclohexylpropan-2-one oximehydrochloride (VI) (R=CH₂ OH; R¹ R² =spirocyclohexyl

A solution of methanol saturated with ammonia was added to3-chloro-2-nitroso-3-spirocyclohexylpropan-1-ol (V) (14.5 g) in atightly secured stoppered flask and the mixture was stirred for threedays at room temperature. The reaction mixture was then refluxed for 1.5h in an atmosphere of ammonia, cooled and filtered. The solvent wasremoved and the residual yellow oil washed with hot benzene anddecanted. The solid was recrystallised from ethanol giving the oximehydrochloride (IV) (7.8 g; yield 50%) as colourless crystals, M.Pt.197°.

EXAMPLE 52-Amino-4-hydroxy-6-(3-hydroxy-2-hydroxyimino-1-spirocyclohexylpropylamino)-5-nitropyrimidine(II) (R=CH₂ OH; R¹ R² =spirocyclohexyl)

A suspension of 2-amino-4-chloro-6-hydroxy-5-nitropyrimidine (III)(Hal=Cl) (2.3 g) in dry ethanol was treated with3-amino-1-hydroxy-3-spirocyclohexylpropan-2-one oxime hydrochloride (IV)(2.5g) and dry triethylamine (2.7 g) and the mixture was refluxed for 7h. The reaction mixture was filtered and the solid washed with hotethanol. The solvent was removed from the filtrate and the resultingyellow oil was triturated with cold water giving a yellow solid which onrecrystallisation from water in the presence of charcoal gave thenitropyrimidine (II) (1.85 g; yield 47.4%) as an off-white powder, m.pt<300° (decomp.).

EXAMPLE 62-Amino-4-hydroxy-6-hydroxymethyl-7-spirocyclohexyl-7,8-dihydropteridine(I) (R=CH₂ OH; (R¹ R² =spirocyclohexyl).

2-Amino-4-hydroxy-6-(3-hydroxy-2-hydroxyimino-1-spirocyclohexylpropylamino)-5-nitropyrimidine(II) (500 mg) was dissolved in the minimum of 0.1M sodium hydroxide bywarming on the steam bath. Sodium dithionite was added portionwise untilan almost colourless solution was obtained. On cooling thedihydropteridine separated and was filtered off and purified bydissolving in 2M HCl and reprecipitated by the addition of 0.88 ammoniato pH8. On standing the dihydropteridine (I) (150 mg; yield 38%) wasobtained as a pale yellow crystalline solid, m.p. <300 (decomp.).

EXAMPLE C

Potential pteridine antagonists of formula (I) may be tested byinvestigating the inhibitory effect they impose on the enzymesresponsible for the biosynthesis of dihydropteroic acid (DPtA), namelyhydroxymethyldihydropteridine pyrophosphokinase (HMPPS), anddihydropteroate synthetase, hereinafter referred to as `synthetase`. Inthe following reaction equations the compounds are referred to by theirabbreviated forms defined on page 5 of the specification.

1. HMPPS ##EQU2##

2. Synthetase ##EQU3##

a. An assay for HMPPS was developed in which the transfer of theterminal phosphate of ATP-γ-p³² to Pt could be monitored and correlatedwith the amount of inhibition of HMPPS by the compound under test.

The compound of formula (I) which was under test was incorporated intovarious formulations comprising metabolites and enzymes contained intest tubes, as indicated in TABLE 1.

The components of the mixture were as follows:

I. 2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine (HMPt) in aconcentration of 800 μM i.e. micromolar;

II. a source of HMPPS, obtained from an extract of E. coli and separatedfrom `synthetase` on sephadex G-100, (Registered Trade Mark) accordingto the method of Richey and Brown in J.Biol.Chem.244, 1582-1592 (1969)

III. 3mM ATP -γ-P³².

IV. 0.10 M ATP neutralised (unlabelled).

V. 0.02M MgCl₂. 6H₂ O.

VI 0.1 M MgCl₂.6H₂ O.

VII Source of HMPPS and `synthetase`

VIII the test compound in a concentration of 0.93×10⁻ ³ M

IX 0.4mM pAB-C¹⁴

As shown in TABLE 1, tubes 1 to 9 all contain a source of HMPPS,labelled ATP and 0.02 M MgCl₂.6H₂ O, tubes 2 to 9 containing in additionHMPt and tubes 4 to 9 further containing the test compound. Controltubes 10 to 12 include a source of both HMPPS and synthetase, unlabelledATP, 0.1M MgCl₂.6H₂ O and labelled pAB.

Tubes 1 to 9 containing the amounts of components shown in the Table,were filled up to 200μ1 with distilled water, incubated for 60 minutesat 37°C and then chilled on ice. Dextrose (20μ1 containing 72.1 mg/ml)and hexokinase (5μ1 containing 2000 units/ml) were added to thesolution, which was then allowed to stand at room temperature for 15minutes. `Darco-G-60` (Registered Trade Mark) (10 mg) was added to eachtube and the contents mixed periodically for 10 minutes. The charcoalwas removed through a `Millipore AP 250 2200` (Registered Trade Mark)filter and the filter was washed with three 10 ml portions of coldwater. The charcoal and the filter were then radioactively counted.

The radioactive count from the contents of tubes 2 and 3 was taken asthe maximum count, since these tubes contained no test compound and thusgave 0% enzyme inhibition. The percentage inhibition produced by thecontents of the remaining tubes could then be calculated by relatingtheir radioactive count to the maximum, as determined above.

The contents of tubes 10 to 12 were chromatographically analysed asdescribed under part (b), and used as controls, tubes 10 and 11containing no test compound (and hence giving 0% inhibition) beingaccorded the value of 100%. The percentage inhibition exhibited by thecontents of the tubes in part (b) of the experiment could then becalculated in relation to this, by comparing the respectivechromatograms. (b) The activity of the test compound of formula (I)against `synthetase` was determined as follows, by monitoring theformation of dihydropteroate C¹⁴.

A pool of Pt was prepared from ATP neutralised (50μl, 0.1M), MgCl₂.6H₂O(50μl,0.1M), dithiothreitol (100μl,0.1M), tris buffer (100μl,0.4M,pH8.3), HMPt (25μl,876μM) and 170μl of a solution containing HMPPS. Themixture was incubated for 60 minutes at 37°C, chilled briefly on ice andthen dextrose (100μl containing 72.1mg/ml and hexokinase (20μlcontaining 2000 units/ml) were added at room temperature to thesolution, which was allowed to stand at this temperature for 15 minutes.

A solution of MgCl₂.6H₂ O (10μl,0.1M), pAB-C¹⁴ (10μl,0.4mM),dithiothreitol (20μl,0.1M) and tris buffer (20μl,0.4M,pH8.3) was made ineach of five test tubes and then 80μl of the contents of the pool addedto each, together with synthetase and/or test compound of formula (I) asindicated in Table 2. The solution was then made up to 200μl withdistilled water.

Two control test tubes were prepared, each containing ATP (10μl,0.1M),MgCl₂.6H₂ O(10μl,0.1M), dithiothreitol (20μl,0.1M) tris buffer(20μl,0.4M,pH 8.3), pAB-C¹⁴ (10μl,0.4mM), and 20μl of a solutioncontaining HMPPS and `synthetase` of known activity. The test compoundwas added to the second of these two tubes up to a final concentrationof 10⁻ ⁵ M, and both tubes were made up with distilled water to 200μl.

All seven tubes were then incubated for 30 minutes at 37°C, chilled onice and then these, together with control tubes 10 to 12 from part (a),were chromatographically analysed as follows.

100μl of the contents of each of the tubes was spotted onto Whatman no.3MM chromatography paper (2×20 cm) at the `origin`, the run descendingin a Sorenson buffer of potassium and sodium phosphates (0.1M,pH 7.0)for 10 to 15 cm. From the relative positions of the spots obtained fromthe contents of the different tubes, the various percentage inhibitionsof synthetase could be evaluated by reference to control tubes 10 and11, which gave 0% inhibition.

Those compounds which, as result of these tests, were found to give 50%inhibition at a concentration of 100μM or less, are those which exert auseful potentiating effect, and subject to their toxicity beingfavourable, may be included in the compositions described in thisspecification.

2-Amino-4-hydroxy-6-hydroxymethyl-7,7-diethyl-7,8-dihydropteridine wasfound to give 50% inhibition at a concentration of 2.1μM.

EXAMPLE D

In this experiment inhibitor zone data were determined to evaluate thesynergistic activity of2-amino-4-hydroxy-6-hydroxymethyl-7,7-diethyl-7,8-dihydropteridine onits combination with trimethoprim (TMP) and/or sulphamethoxazole (SMX)against Staphylococcus aureus.

The pteridine was included in a soya peptone medium of low thymidinecontent (Wellcotest Sensitivity test agar) contained in a Petri dish andthe other component(s) added to the well resulting from the removal of asmall plug from the medium. The surface of the medium was inoculatedwith the test organism and then incubated. The amount of zone inhibitionis shown in Table 3, wherein the numbers represent the complete zoneinhibition (i.e. the number of centimeters from the edge of the wellafter about 6 × magnification) and the figures in parenthesis includethe zones of partial inhibition.

The Results show that the pteridine shows synergism with TMP and SMXalone and multiple synergism with both against Staphylococcus aureus.

                  Example E                                                       ______________________________________                                        Tablet Formulation                                                            Compound of formula (I)(R= CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                               100 mg                                           Trimethoprim (pure)          25 mg                                            Sulfaguanidine (B.P.C.)      100 mg                                           + cornstarch, lactose, gelatin, talcum and                                    magnesium stearate                                                            ______________________________________                                    

Preparation

The above constituents were mixed together using known methods ofpharmacy to form a granulation which was then compressed into tablets.

                  Example F                                                       ______________________________________                                        Tablet Formulation                                                            "Pyremathimine" (Pyrimethamine) B.P.                                                                       15 mg                                            Compound of forumua (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                                150 mg                                           which was then prepared to form a tablet as in                                Example E.                                                                    ______________________________________                                        Example G                                                                     ______________________________________                                        Tablet Formulation                                                            Sulfanilamide B.P.C.         150 mg                                           Compound of formula (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                                175 mg                                           which was then prepared to form a tablet as in                                Example E.                                                                    ______________________________________                                        Example H                                                                     ______________________________________                                        Capsule Formulation                                                           Trimethoprim (pure)          20 mg                                            Compound of formula (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 Et)                                                 100 mg                                           ______________________________________                                    

Preparation

The compounds in granular form were blended together with lactose,cornstarch and magnesium stearate. The powder was filled into atwo-piece, hard shell gelatin capsule using a capsulating machine.

                  Example I                                                       ______________________________________                                        Irrigant Solution                                                             Compund of formula (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                               1 mg/ml                                            (pure)                                                                        Trimethoprim (pure)        0.2 mg/ml                                          Solvent                    water                                              ______________________________________                                        Example J                                                                     ______________________________________                                        Irrigant Solution                                                             Compound of formula (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                              2 mg/ml                                            (pure)                                                                        α-amino-p-toluenesulphonamide (pure)                                                               2 mg/ml                                            ______________________________________                                        EXAMPLE K                                                                     ______________________________________                                        Solution                                                                      Compound of formula (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                              1.5 mg/ml                                          (pure)                                                                        Diaveridine B. Vet C       0.5 mg/ml                                          Kelfizina                  1.0 mg/ml                                          Solvent                    water                                              ______________________________________                                        Example L                                                                     ______________________________________                                        Tablet Formulation                                                            Compound of formula (I)(R=CH.sub.2 OH;R.sup.1 =R.sup.2 =Et)                                              500 mg                                             (pure)                                                                        Microcrystalline cellulose 100 mg                                             Starch                     40 mg                                              Magnesium stearate         10 mg                                              Methylhydroxyethylcellulose                                                                              3 mg                                                                          653 mg                                             ______________________________________                                    

The pteridine (I), microcrystalline cellulose and starch were granulatedwith a solution of the methylhydroxyethylcellulose in 50% aqueous ethylalcohol. The magnesium stearate was added to the dried granules, and thewhole then compressed.

                                      TABLE 1                                     __________________________________________________________________________    Tube No.                                                                            I   II   III IV  V   VI  VII VIII   IX                                                                     Final                                                                         Concn.                                     __________________________________________________________________________    1     --  100μl                                                                           15μl                                                                           --  10μl                                                                           --  --  --     --                                  2     5μl                                                                            "    "   --  "   --  --  --     --                                  3     "   "    "   --  "   --  --  --     --                                  4     "   "    "   --  "   --  --  2.5×10.sup.-.sup.6 M                                                           --                                  5     "   "    "   --  "   --  --  "      --                                  6     "   "    "   --  "   --  --  1.0×10.sup.-.sup.5 M                                                           --                                  7     "   "    "   --  "   --  --  "      --                                  8     "   "    "    -- "   --  --  9.3×10.sup.-.sup.5 M                                                           --                                  9     "   "    "   --  "   --  --  "      --                                  Controls                                                                      10    --  --   --  10μl                                                                           --  10μl                                                                           20μl    10μl                             11    5μl                                                                            --   --  "   --  "   "          "                                   12    "   --   --  "   --  "   "   1.0×10.sup.-.sup.5 M                                                           "                                   __________________________________________________________________________

                  TABLE 2                                                         ______________________________________                                        Tube No.   Excess        Test compound                                                   Synthetase    Final Concen-                                                                 tration.                                             ______________________________________                                        1          --            --                                                   2          +             --                                                   3          +             8.7×10.sup.-.sup.5 M                           4          +             1.0×10.sup.-.sup.5 M                           5          +             2.5×10.sup.-.sup.6 M                           Controls                                                                      6          --            --                                                   7          --            1.0×10.sup.-.sup.5 M                           ______________________________________                                    

                  TABLE 3                                                         ______________________________________                                        Staphylococcus aureus                                                         Drug     TMP         SMX         TMP + SMX                                    (μg/ml)                                                                             (30)        (300)        (5)   (100)                                 ______________________________________                                        R=CH.sub.2 OH                                                                          12.5(17.0)  12.5(17.0)  12.5(17.0)                                   R.sup.1 =R.sup.2 =Et                                                          (30)                                                                          "        10.5(13.0)  10.5(14.0)  11.0(14.5)                                   (10)                                                                          "         8.5(10.5)   6.5(12.5)  10.5(12.5)                                   (3)                                                                           ______________________________________                                    

What we claim is:
 1. A compound of the formula, or a tautomeric formthereof ##SPC5##wherein Z is oxygen or a protecting group therefore, Ris lower alkyl or hydroxylower alkyl, and R¹ and R², having in total 4to 6 carbon atoms, form a spirocycloalkyl group together with the carbonatom substituted by said R¹ and R².
 2. The compound according to claim1, which is2-Amino-4-hydroxy-6-(3-hydroxy-2-hydroxyimino-1-spirocyclohexylpropylamino)-5-nitropyrimidine.